drugset / Trial / NCT05652647

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

NCT05652647

Phase 1 Completed 6 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this clinical trial is to learn about how much PF-07081532 will be taken up and processed by healthy male participants. The study consists of two parts, called study periods. In Period 1, participants will take one dose of PF-07081532 by mouth. In Period 2, participants will take one dose by mouth and one dose as an injection through a vein at the study clinic. In Period 1, participants will stay at the clinic site for up to 21 days. In Period 2, they will stay at the clinic site for 7 days. During their stays, participants will have their blood, urine, and feces collected by the study doctors several times. We will measure the level of PF-07081532 in participants' blood, urine, and feces samples. This will help us know how much the study medicine is getting taken in by the body. At the end of the study, participants will be contacted by phone to check in. Participants will be involved in this study for about 12 weeks.

Timeline

Start
2022-12-21
Primary completion
2023-03-15
Completion
2023-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject lotiglipron Small molecule Oral

Indications

No indication recorded.